neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.
Company profile
Ticker
NBSE
Exchange
Website
CEO
Dietrich Stephan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BBM HOLDINGS, INC., Ohr Pharmaceutical Inc, PRIME RESOURCE INC
SEC CIK
Corporate docs
Subsidiaries
NeuBase Corporation • Ohr Opco, Inc. • Ohr Pharma, LLC ...
IRS number
133709558
NBSE stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
9 Apr 24
8-K
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
5 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
8-K
Other Events
7 Mar 24
8-K
Other Events
23 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Jan 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Termination of a Material Definitive Agreement
28 Dec 23
424B3
Prospectus supplement
28 Dec 23
8-K
Termination of a Material Definitive Agreement
22 Dec 23
Transcripts
Latest ownership filings
SC 13G/A
GREENLIGHT CAPITAL INC
14 Feb 24
5
Aleta Shiff
20 Sep 23
SC 13D/A
Symetryx Corp
20 Sep 23
4
Change in insider ownership
18 Sep 23
SC 13D/A
Symetryx Corp
14 Sep 23
3/A
Aleta Shiff
12 Sep 23
4
Change in insider ownership
11 Sep 23
4
Change in insider ownership
7 Sep 23
3
Initial statement of insider ownership
1 Sep 23
SC 13D
Symetryx Corp
31 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm | 12.57 mm |
Cash burn (monthly) | 725.69 k | 881.86 k | 937.73 k | 1.27 mm | 667.52 k | 1.23 mm |
Cash used (since last report) | 4.82 mm | 5.85 mm | 6.22 mm | 8.44 mm | 4.43 mm | 8.18 mm |
Cash remaining | 7.75 mm | 6.72 mm | 6.35 mm | 4.13 mm | 8.14 mm | 4.39 mm |
Runway (months of cash) | 10.7 | 7.6 | 6.8 | 3.2 | 12.2 | 3.6 |
Institutional ownership, Q2 2023
52.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 5 |
Closed positions | 17 |
Increased positions | 0 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 866.46 mm |
Total shares | 1.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kershner Trading Americas,LLC | 1.50 mm | $310.00 k |
Armistice Capital | 166.17 k | $310.75 mm |
Greenlight Capital | 136.35 k | $254.98 mm |
Point72 Asset Management | 62.50 k | $116.88 mm |
Kestra Advisory Services | 25.48 k | $47.65 mm |
Vanguard | 18.98 k | $35.49 mm |
Jacob Asset Management Of New York | 15.66 k | $28.96 mm |
Prelude Capital Management | 15.55 k | $29.08 mm |
Renaissance Technologies | 12.60 k | $24.00 k |
Geode Capital Management | 11.70 k | $21.64 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.19 | 50,000 | 59.50 k | 0 |
15 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.26 | 103,337 | 130.20 k | 50,000 |
14 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.44 | 129,108 | 185.92 k | 153,337 |
11 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.44 | 3,376 | 4.86 k | 472,926 |
8 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.53 | 128,847 | 197.14 k | 476,302 |
7 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Sell | Dispose S | No | No | 1.8 | 74,852 | 134.73 k | 605,149 |
1 Sep 23 | Symetryx | Common Stock, Par Value $0.0001 per Share | Buy | Acquire P | No | No | 0.978 | 61,076 | 59.73 k | 680,081 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
12 Apr 24
NeuBase Therapeutics Received A Notice On April 4, 2024 From The Listing Qualifications Department Of The Nasdaq Stock Market Notifying The Company That It Was Not In Compliance With Nasdaq's Continued Listing Requirements Under Nasdaq Listing Rule 5250(c)(1)
5 Apr 24
Why Neubase Therapeutics (NBSE) Shares Are Nosediving
26 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
26 Mar 24